American Journal of Tropical Medicine and Hygiene · 2009 · 15 citations · 23 references
MedicineInfectious DiseasesPharmacologyAntimicrobial PharmacologyParasite EpidemiologyPharmacodynamicsAntimicrobial Susceptibility TestingAntiparasitic AgentsAntiparasitic ChemotherapyAntiparasitic PharmacologyAntiparasitic TherapyMalariaAntimalarial AgentsAntimalarial ChemotherapyMalaria ResistanceMalaria SusceptibilityPlasmodium FalciparumPlasmodium VivaxTreatment Of Malaria
The antimalarial susceptibility of ring stage (> 80%) Plasmodium vivax from the Republic of Korea, where long incubation-period strains are prevalent, was evaluated using the schizont maturation inhibition technique. During 2005-2007, susceptibility to seven antimalarial drugs was evaluated with 24 fresh isolates. The geometric mean (95% confidence interval) 50% inhibition concentration (IC(50)) were quinine 60 (54-75) ng/mL, chloroquine 39 (22-282) ng/mL, piperaquine 27 (17-58) ng/mL, mefloquine 39 (35-67) ng/mL, pyrimethamine 138 (89-280) ng/mL, artesunate 0.6 (0.5-0.8) ng/mL, and primaquine 122 (98-232) ng/mL. Positive correlations were found between quinine and mefloquine (r = 0.6, P = 0.004), piperaquine and chloroquine (r = 0.6, P = 0.008), and piperaquine and primaquine IC(50) values (r = 0.5, P = 0.01). Compared with P. vivax in Thailand, P. vivax in the Republic of Korea was more sensitive to quinine and mefloquine, but equally sensitive to chloroquine and artesunate.
23
Effects of Plasmodium vivax malaria in pregnancy
François Nosten, Rose McGready, J. A. Simpson et al. · The Lancet · 1999 · 389 citations
Armedy Ronny Hasugian, Hermawan Purba, Enny Kenangalem et al. · Clinical Infectious Diseases · 2007 · 155 citations · Full text